Hempacco Receives Notification of Deficiency from Nasdaq
Hempacco (NASDAQ: HPCO), a vertically integrated hemp manufacturing company, has received a written notice from Nasdaq's Listing Qualifications Department regarding its failure to file the Quarterly Report on Form 10-Q for the period ended June 30, 2024. This delinquency serves as an additional basis for potential delisting of the company's securities from Nasdaq.
The notice indicates that Nasdaq's hearings panel will consider this matter in their decision about Hempacco's continued listing. The company is working to complete and file its delinquent Quarterly Reports and plans to present its views on this deficiency to the hearings panel by August 27, 2024.
Hempacco (NASDAQ: HPCO), un'azienda di produzione di canapa a integrazione verticale, ha ricevuto una notifica scritta dal Dipartimento per le Qualificazioni di Quotazione di Nasdaq riguardo alla sua mancata presentazione del Rapporto Trimestrale sul Modulo 10-Q per il periodo conclusosi il 30 giugno 2024. Questa inadempienza costituisce una basi aggiuntive per una potenziale delisting dei titoli della società da Nasdaq.
La notifica indica che il pannello di udienza di Nasdaq prenderà in considerazione questa questione nella loro decisione sulla continuazione della quotazione di Hempacco. L'azienda sta lavorando per completare e presentare i suoi Rapporti Trimestrali in ritardo e prevede di esporre le sue opinioni su questa carenza al pannello di udienza entro il 27 agosto 2024.
Hempacco (NASDAQ: HPCO), una empresa de fabricación de cáñamo verticalmente integrada, ha recibido un aviso por escrito del Departamento de Calificaciones de Listado de Nasdaq respecto a su incumplimiento en la presentación del Informe Trimestral en el Formulario 10-Q para el periodo finalizado el 30 de junio de 2024. Este incumplimiento sirve como una base adicional para un posible deslisteo de los valores de la empresa de Nasdaq.
El aviso indica que el panel de audiencias de Nasdaq considerará este asunto en su decisión sobre la continuación del listado de Hempacco. La empresa está trabajando para completar y presentar sus Informes Trimestrales pendientes y planea presentar sus puntos de vista sobre esta deficiencia al panel de audiencias antes del 27 de agosto de 2024.
험파코 (NASDAQ: HPCO), 수직 통합 대마 제조 회사는 나스닥 상장 자격 부서로부터 서면 통지를 받았습니다 이것은 2024년 6월 30일 종료된 분기 보고서인 10-Q 형식의 분기 보고서를 제출하지 못한 것에 대한 것입니다. 이 불이행은 회사의 자산이 나스닥에서 상장 폐지될 가능성에 대한 추가적인 근거가 됩니다.
통지에 따르면 나스닥 청문 위원회는 헴팜코의 지속적 상장 여부에 대한 결정에서 이 문제를 고려할 것입니다. 이 회사는 미제출된 분기 보고서를 완료하고 제출하기 위해 노력하고 있으며 2024년 8월 27일까지 청문 위원회에 이 결점에 대한 의견을 제시할 계획입니다.
Hempacco (NASDAQ: HPCO), une entreprise de fabrication de chanvre à intégration verticale, a reçu une notification écrite du département des qualifications de listing de Nasdaq concernant son échec à déposer le rapport trimestriel sur le formulaire 10-Q pour la période se terminant le 30 juin 2024. Ce manquement constitue une base supplémentaire pour un éventuel retrait de cotation des titres de l'entreprise de Nasdaq.
La notification indique que le panel d'audition de Nasdaq examinera cette affaire dans sa décision concernant la poursuite de la cotation de Hempacco. L'entreprise travaille pour compléter et déposer ses rapports trimestriels en retard et prévoit de présenter ses points de vue sur cette carence au panel d'audition d'ici le 27 août 2024.
Hempacco (NASDAQ: HPCO), ein vertikal integriertes Unternehmen für Hanfherstellung, hat eine schriftliche Mitteilung von der Abteilung für Listungsqualifikationen von Nasdaq bezüglich seiner Nichtabgabe des Quartalsberichts im Formular 10-Q für den Zeitraum bis zum 30. Juni 2024 erhalten. Diese Versäumnis dient als zusätzliche Grundlage für eine mögliche Delistierung der Wertpapiere des Unternehmens von Nasdaq.
Die Mitteilung weist darauf hin, dass das Anhörungsgremium von Nasdaq diese Angelegenheit bei ihrer Entscheidung über die weitere Listung von Hempacco berücksichtigen wird. Das Unternehmen arbeitet daran, die überfälligen Quartalsberichte zu vervollständigen und einzureichen und plant, seine Sichtweise zu diesem Mangel dem Anhörungsgremium bis zum 27. August 2024 darzulegen.
- Hempacco is actively working to complete and file its delinquent Quarterly Reports
- The company plans to present its views to the Nasdaq hearings panel by August 27, 2024
- Hempacco received a notification of deficiency from Nasdaq
- The company is delinquent in filing its Quarterly Report on Form 10-Q for Q2 2024
- This deficiency serves as an additional basis for potential delisting from Nasdaq
- Hempacco's continued listing on Nasdaq is at risk
Hempacco's notification of deficiency from Nasdaq is a serious concern for investors. The company's failure to file its Q2 2024 10-Q report on time indicates potential financial reporting issues or internal control weaknesses. This delinquency, combined with previous listing compliance problems, significantly increases the risk of delisting from Nasdaq. A delisting would severely impact stock liquidity and investor confidence.
The company's statement about working to complete the filing and present its case to the hearings panel by August 27, 2024, provides little reassurance. Investors should be cautious as this situation could lead to restricted trading or a move to over-the-counter markets, potentially resulting in substantial value loss for shareholders. The lack of timely financial information also makes it challenging to assess Hempacco's current financial health and performance.
This notification escalates Hempacco's regulatory compliance issues to a critical level. The company now faces a multi-faceted delisting threat, with the late 10-Q filing compounding existing problems. The Nasdaq hearings panel will likely scrutinize Hempacco's overall compliance history and ability to meet listing requirements going forward.
Investors should be aware of potential legal ramifications. Late filings can trigger SEC investigations and shareholder lawsuits, especially if material information was withheld or misrepresented. The company's ability to remedy this situation quickly is crucial. If Hempacco fails to file by August 27, 2024, or if the panel is unsatisfied with their explanation, a delisting decision could be imminent, potentially leading to breach of contract issues with business partners and lenders.
San Diego, California--(Newsfile Corp. - August 23, 2024) - Hempacco Co., Inc. (NASDAQ: HPCO) ("Hempacco" or the "Company"), a vertically integrated hemp manufacturing company, received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2024, that this matter serves as an additional basis for delisting the Company's securities from the Nasdaq, and that Nasdaq's hearings panel will consider this matter in their decision regarding the Company's continued listing on the Nasdaq.
The Nasdaq listing rules require listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Company is working to complete and file its delinquent Quarterly Reports on Form 10-Q and intends to present its views with respect to this deficiency to the hearings panel by August 27, 2024.
About Hempacco
Hempacco Co., Inc.'s goal is Disrupting Tobacco's™ nearly
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: (i) potential failure to meet projected development and related targets; (ii) changes in applicable laws or regulations that may impact our products and business; (iii) the effect of geopolitical and economic conditions on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221035
FAQ
Why did Hempacco (HPCO) receive a notification of deficiency from Nasdaq?
What are the potential consequences for Hempacco (HPCO) due to this Nasdaq notification?
How is Hempacco (HPCO) responding to the Nasdaq deficiency notice?
When is Hempacco (HPCO) expected to address the Nasdaq hearings panel about the deficiency?
